HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC/Supplement Co-Packaging Policy In The Works At FDA

This article was originally published in The Tan Sheet

Executive Summary

Any future FDA guidance or regulation on co-packaging OTCs with dietary supplements would have to reflect the agency's resolution of concerns related to duration of use, dual-labeling and multiple claims for such products

You may also be interested in...

OTC/Supplement Combo Products Are In “Regulatory Limbo” – Attorney

FDA should include OTC drug/dietary supplement combinations in its combination products guidelines and place them under the jurisdiction of the Office of Combination Drugs, attorney Ralph Fucetola recommends

OTC/Supplement Combo Guidance, Sale Urged By Rep. Burton

House Government Reform Committee Chair Dan Burton (R-Ind.) is pressing FDA to explain its intentions regarding OTC drug/dietary supplement combination products

OTC/Dietary Supplement Combos Cited In FDA Warning Letters

The presence of acetaminophen in OTC/dietary supplement combination products renders them drugs, FDA says in recent warning letters to two companies.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts